New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
07:38 EDTHZNPHorizon Pharma to receive approval from UK MHRA
Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization for Duexis, pending review of updated licensing documents which the Company has provided to the MHRA. The MA of Duexis is for the treatment of osteoarthritis, or OA, rheumatoid arthritis, or RA, and ankylosing spondylitis, or AS, and to decrease the risk of developing upper gastrointestinal ulcers. Duexis is approved and available in the United States.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
November 14, 2014
08:06 EDTHZNPHorizon Pharma 11.66M share Secondary priced at $12.05
Subscribe for More Information
November 13, 2014
14:56 EDTHZNPHorizon Pharma says Watson Labs filed ANDA for generic PENNSAID
Subscribe for More Information
07:06 EDTHZNPHorizon Pharma files to sell 11.66M shares for existing holders
Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.
November 12, 2014
08:09 EDTHZNPHorizon Pharma announces favorable Markman ruling in RAYOS patent trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use